180 related articles for article (PubMed ID: 17483358)
21. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.
Vlahov IR; Santhapuram HK; Kleindl PJ; Howard SJ; Stanford KM; Leamon CP
Bioorg Med Chem Lett; 2006 Oct; 16(19):5093-6. PubMed ID: 16870437
[TBL] [Abstract][Full Text] [Related]
22. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
23. Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.
Patel VF; Hardin JN; Mastro JM; Law KL; Zimmermann JL; Ehlhardt WJ; Woodland JM; Starling JJ
Bioconjug Chem; 1996; 7(4):497-510. PubMed ID: 8853464
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients.
Li J; Sausville EA; Klein PJ; Morgenstern D; Leamon CP; Messmann RA; LoRusso P
J Clin Pharmacol; 2009 Dec; 49(12):1467-76. PubMed ID: 19837906
[TBL] [Abstract][Full Text] [Related]
25. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
26. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
Worzalla JF; Shih C; Schultz RM
Anticancer Res; 1998; 18(5A):3235-9. PubMed ID: 9858888
[TBL] [Abstract][Full Text] [Related]
27. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.
Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP
Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.
Leamon CP; Reddy JA; Vlahov IR; Vetzel M; Parker N; Nicoson JS; Xu LC; Westrick E
Bioconjug Chem; 2005; 16(4):803-11. PubMed ID: 16029021
[TBL] [Abstract][Full Text] [Related]
29. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
30. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.
Sega EI; Lu Y; Ringor M; Leamon CP; Low PS
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004
[TBL] [Abstract][Full Text] [Related]
31. [Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
Tsujimoto H; Tsukioka S; Koizumi K; Nakagawa F; Uchida J; Sugimoto Y; Oka T; Fukushima M; Watanabe T
Gan To Kagaku Ryoho; 2007 Mar; 34(3):413-8. PubMed ID: 17353633
[TBL] [Abstract][Full Text] [Related]
32. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Edelman MJ; Harb WA; Pal SE; Boccia RV; Kraut MJ; Bonomi P; Conley BA; Rogers JS; Messmann RA; Garon EB
J Thorac Oncol; 2012 Oct; 7(10):1618-21. PubMed ID: 22982661
[TBL] [Abstract][Full Text] [Related]
33. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
[TBL] [Abstract][Full Text] [Related]
34. High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Guertin AD; O'Neil J; Stoeck A; Reddy JA; Cristescu R; Haines BB; Hinton MC; Dorton R; Bloomfield A; Nelson M; Vetzel M; Lejnine S; Nebozhyn M; Zhang T; Loboda A; Picard KL; Schmidt EV; Dussault I; Leamon CP
Mol Cancer Ther; 2016 Aug; 15(8):1998-2008. PubMed ID: 27256377
[TBL] [Abstract][Full Text] [Related]
35. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates.
Vlahov IR; Santhapuram HK; You F; Wang Y; Kleindl PJ; Hahn SJ; Vaughn JF; Reno DS; Leamon CP
J Org Chem; 2010 Jun; 75(11):3685-91. PubMed ID: 20423159
[TBL] [Abstract][Full Text] [Related]
36. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Ambrosio AJ; Suzin D; Palmer EL; Penson RT
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
[TBL] [Abstract][Full Text] [Related]
37. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
Kukowska-Latallo JF; Candido KA; Cao Z; Nigavekar SS; Majoros IJ; Thomas TP; Balogh LP; Khan MK; Baker JR
Cancer Res; 2005 Jun; 65(12):5317-24. PubMed ID: 15958579
[TBL] [Abstract][Full Text] [Related]
39. Vintafolide: a novel targeted agent for epithelial ovarian cancer.
Graybill WS; Coleman RL
Future Oncol; 2014 Mar; 10(4):541-8. PubMed ID: 24754586
[TBL] [Abstract][Full Text] [Related]
40. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.
Schroeder JE; Shweky I; Shmeeda H; Banin U; Gabizon A
J Control Release; 2007 Dec; 124(1-2):28-34. PubMed ID: 17928088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
